ACL is a company with patent granted technologies in brain science. 
ACL is a licensed manufacturer by Pennsylvania State government for our medical food products.

After achieving miraculous therapy for early and mid stage Alzheimer’s patients by our flagship product BrainGlucose, Able Cerebral is migrating gradually to a pharmaceutical and medical device company in order ​to improve health in more areas:

1. Advancing our BrainGlucose to phase III clinical study so it can be available to more patients as a drug product.

2. Welcome Investments and Collaborations for continuing our efforts to develop AddMem, a non invasive medical device with game changing technologies for individualized memory recovery. It may benefit severe stage Alzheimer's, TBI (traumatic brain injury) and CTE (chronic traumatic encephalopathy).
​
3. These patented technologies is the basis of brain-machine interface. It can be the next AI (Artificial Intelligence) area to be explored based on our brain circuits theory--free energy, functional group interaction and memory protein stability equilibrium. 

4. Expanding our technology and product line to appetite control / weight management (ChewFull), and digestive system strengthening (IBSshield).

​5. Our patented technology can provide pharmaceutical companies competitive edge by reducing various medications' CNS side effects without increase costs, which is very important in a trend of patients and 3rd party differentiating payment system.


​Interested institutions for partnership and/or investment
​
Please contact:

Mr. Wayne Shentu

55 New Street, Ste. 14
Ephrata, PA 17522, U.S.
Tel: (717) 814-5752
​communication@ablecerebral.com

In memory of Professor J. Howard Rytting, a diabetic and devoted his knowledge of thermodynamics to bio-pharmaceutical research